Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSystem1 Group Regulatory News (SYS1)

Share Price Information for System1 Group (SYS1)

Share Price is delayed by 15 minutes
Get Live Data
311.00    -14.00 (-4.31%)
Bid:
310.00
Ask:
312.00
Spread: 2.00 (0.645%)
Market Cap: £39.46m
SYS1 Live PriceLast checked at - London Stock Exchange

Intraday System1 Group Share Chart

Global Expansion

16 Jun 2008 07:00

RNS Number : 7214W
BrainJuicer Group PLC
16 June 2008
Β 

ο»Ώ

Press ReleaseΒ 

16Β JuneΒ 2008

BrainJuicer GroupΒ PLC

("BrainJuicer" or "the Company")

BrainJuicerΒ furthers global expansion withΒ 

AustralianΒ licenceΒ andΒ SwissΒ officeΒ opening

Β 

Β 

BrainJuicer GroupΒ PLC, (AIM: BJU), a leadingΒ international onlineΒ marketΒ research agency,Β today announces that it hasΒ furtheredΒ its globalΒ expansion strategyΒ byΒ establishingΒ a presenceΒ in both AustraliaΒ andΒ Switzerland,Β whereΒ a numberΒ of itsΒ existing and potential multinationalΒ clientsΒ have a regional head office. This expansion buildsΒ on theΒ Company'sΒ existing officesΒ in theΒ UK, USΒ andΒ theΒ Netherlands.Β Β 

Australian licenceΒ agreementΒ 

BrainJuicer has agreed to license its products to Slater Marketing Group Pty Ltd ("Slater"), a long-established market research firm based inΒ Melbourne. This firstΒ strategicΒ licensing deal for BrainJuicer has beenΒ drivenΒ by the importance ofΒ AustraliaΒ for the Company's multinational clients. TheΒ agreement providesΒ anΒ opportunityΒ toΒ generateΒ new revenuesΒ for BrainJuicerΒ in theΒ region, and there are a number ofΒ existingΒ clientsΒ thereΒ alreadyΒ benefiting fromΒ BrainJuicer's innovativeΒ products, including FostersΒ Group, Fonterra (one of theΒ largest dairy companies inΒ Australia), andΒ CampbellΒ Arnott's.Β 

The licence agreementΒ allows Slater to sellΒ BrainJuicer'sΒ services inΒ AustraliaΒ andΒ New ZealandΒ on a profitΒ share arrangement, which will lead to the acquisition ofΒ SlaterΒ dependent on a series of financial targets. TheΒ Company has purchasedΒ 3.64%Β ofΒ SlaterΒ andΒ agreed toΒ purchaseΒ theΒ remainderΒ ofΒ theΒ business once pre-agreed financial targets have been met,Β for a totalΒ considerationΒ ofΒ AU$2.2 million. The staged structureΒ ofΒ the transactionΒ allowsΒ BrainJuicer to enter thisΒ newΒ marketΒ in a phased manner.

Swiss office opening

TheΒ Company also announces today that itΒ isΒ openingΒ anΒ officeΒ inΒ Switzerland,Β which isΒ a key strategicΒ marketΒ forΒ BrainJuicer'sΒ continuedΒ expansion.

BrainJuicer has appointed Mark Johnson as the country manager in order to build on the Company's existing client base in this territory. Mark has over 10 years' experience in consumer insight and market research, and with his strong track record of innovation he will be building a team to service Swiss-based clients. He has worked for research and innovation consultancies first in London, then Paris and most recently for Cereal Partners Worldwide in Lausanne (the joint venture between Nestlé and General Mills). By opening this office the Company will be in a position to tap into the significant number of multi-national companies which have their European head offices located there.

John Kearon,Β CEOΒ ofΒ BrainJuicer, commented: "We are delighted to announce the further expansion of the business,Β which reinforces BrainJuicer's strategy of broadening our geographical reachΒ by identifying regions in which ourΒ existing and potential clientsΒ have regional head offices, andΒ thereforeΒ aligning ourselves withΒ theseΒ large multinational companies. Slater is an ideal fit for BrainJuicer, both in terms of its ethos and its client base. TheΒ agreementΒ will haveΒ considerableΒ benefit for both parties, as BrainJuicer's innovative products will enhance Slater's current offering, and Slater will give BrainJuicer access to this new territory.

"The opening of the Swiss office marks a significant step in terms of our presence inΒ Europe. We have chosen a region in which we already have a number of clientsΒ andΒ whichΒ houses the EuropeanΒ head offices ofΒ many of the world's largest companies, includingΒ Nestle,Β General Mills, Proctor & Gamble, Roche and Philip Morris.Β Β Our physical presenceΒ thereΒ will give us greater ability to growΒ ourΒ client base, and we are delighted to have attracted someone of Mark'sΒ calibreΒ to establish this office;Β his strategic marketing approach will be of great benefit to the Company, and we look forward to his contribution to the ongoing innovation within BrainJuicer.

"The Board is excited about expandingΒ BrainJuicer's global operations. We look forward to updating the market on theΒ successful rollout of the licence agreement with Slater, as well as the anticipated growth of the Swiss office."

- Ends -

Β 

For further information, please contact:

BrainJuicer plc

John Kearon, Chief Executive Officer

Tel: +44 (0)20 7043 1000Β 

James Geddes, Chief Financial Officer

www.brainjuicer.com

Landsbanki Securities (UK) Limited

Nomad & Broker

Fred Walsh / Simon Brown

Tel: +44Β (0)20Β 7426Β 9000

Β 

www.landsbanki.co.ukΒ 

UKΒ media enquiries:

Abchurch Communications

Tel: +44 (0) 20 7398 7700

Heather SalmondΒ /Β Joanne Shears

Tel: +44 (0) 20 7398 7709

joanne.shears@abchurch-group.com

www.abchurch-group.comΒ 

US media enquiries:

BrainJuicer plc

Susan Griffin, VP Marketing and Business Development

Tel: +191 72 168 940

Notes to Editors

BrainJuicer carries out quantitative online research using innovative, bespoke software to produce insightful market research for large, multinational companies, including 15 of the world's top 100Β companies (FT 500 September 2006).

BrainJuicer operates in a growing sector of the US$25bn global research market, namely quantitative online research. BrainJuicer's main competitors are large traditional market research providers who have dominated the market for off-line market research, such as AC Nielsen, Millward Brown, Research International and Taylor Nelson Sofres.

Whilst the largest traditional research companies have developed their own online capability, BrainJuicer has a number of key attributes which have contributed to it achieving rapid growth and winning contracts with prestigious clients, including:

β€’Β Research platform that delivers greater diagnostic insight.Β BrainJuicer has developed tools and award-winning techniques that enable it to provide a greater level ofΒ qualitativeΒ diagnostic insight into quantitative market research. These techniques enable clients to enhance their understanding of consumer preference and help them make decisions on the best way to develop their products and services.

β€’Β Speed.Β BrainJuicer's automated research techniques enable it to conduct complicated studies very quickly. BrainJuicer's rapid deployment and results production, even on multi-country studies, provide clients with a speed to market advantage in the development of new products and services.

β€’Β A scaleable online-only business model.Β Unlike the traditional research companies who maintain both on and offline data collection capabilities, BrainJuicer is able to focus on operating a scaleable online-only business model.

To date the Group has conducted projects in over 50 countries and more than 30 languages and has established offices in theΒ UK, theΒ NetherlandsΒ and theΒ US.

The Group's revenues come from full service market research work, and from its online Juicy Brains Panel in theΒ UK.

Further information on BrainJuicer can be found atΒ www.brainjuicer.comΒ .

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
MSCSFWFIDSASELM
Date   Source Headline
1st May 20264:30 pmRNSHolding(s) in Company
21st Apr 20267:01 amRNSRelationship Agreement with Brave Bison
21st Apr 20267:00 amRNSQ4 and Full Year Trading Update
9th Apr 20267:00 amRNS-RLaunch of next evolution of Test Your Ad platform
30th Mar 20264:30 pmRNSHolding(s) in Company
30th Mar 20263:30 pmRNSDirector/PDMR Shareholding
16th Mar 20267:00 amRNSTrading Update
16th Mar 20267:00 amRNSTrading Update
5th Mar 20263:15 pmRNSDirector/PDMR Shareholding
3rd Mar 20265:15 pmRNSHolding(s) in Company
3rd Mar 20264:06 pmRNSBoard Change
2nd Mar 20261:39 pmRNSShareholder update & PDMR Dealing
2nd Mar 20267:00 amRNSDirectorate change
30th Jan 20261:00 pmRNSBoard Committee and Change of Role Update
20th Jan 20267:00 amRNSTrading Update
12th Jan 20264:45 pmRNSAppointment of Joint Corporate Broker
2nd Dec 20257:00 amRNSInterim Results
20th Nov 202511:45 amRNSHolding(s) in Company
24th Oct 20253:28 pmRNSHolding(s) in Company
22nd Oct 20257:00 amRNSTrading Update
14th Oct 20259:16 amRNSCapital Markets Day
6th Oct 20253:30 pmRNSDirector/PDMR Shareholding
30th Sep 20257:00 amRNSDirector/PDMR Shareholding - replacement
29th Sep 20255:48 pmRNSDirector/PDMR Shareholding
29th Sep 20251:27 pmRNSHolding(s) in Company
26th Sep 20252:29 pmRNSHolding(s) in Company
26th Sep 20257:00 amRNSDirector/PDMR Shareholding
24th Sep 20253:01 pmRNSResult of AGM
23rd Sep 20257:00 amRNSTrading Update
15th Sep 20251:00 pmRNSDirector/PDMR Shareholding
27th Aug 20254:51 pmRNSNotice of AGM
8th Aug 20254:35 pmRNSDirector/PDMR Shareholding
9th Jul 20257:00 amRNSDirector Role Change
9th Jul 20257:00 amRNSFinal Results
9th Jul 20257:00 amRNSTrading Update
4th Jul 202511:45 amRNSHolding(s) in Company
4th Jul 20257:00 amRNSHolding(s) in Company
16th Jun 20251:30 pmRNSHolding(s) in Company
14th May 20257:00 amRNSEstablishment of New Long-Term Incentive Plan
24th Apr 20251:53 pmRNSHolding(s) in Company
23rd Apr 20257:00 amRNSTrading Statement
23rd Jan 20257:00 amRNSHolding(s) in Company
21st Jan 20257:00 amRNSTrading Update
8th Jan 202510:15 amRNSHolding(s) in Company
3rd Dec 20247:00 amRNSInterim Results
28th Nov 20247:00 amRNSInterim Results Presentation
21st Nov 20243:31 pmRNSHolding(s) in Company
28th Oct 202410:15 amRNSDirector/PDMR Shareholding
23rd Oct 20247:00 amRNSDirector/PDMR Shareholding
22nd Oct 20247:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.